This is not a new demonstration format. It follows our existing public case validation process for verifying Minerva Advisor's decision support capability. The source is an official public Analysis Group case. We first isolated the later stage published answer, then reconstructed what was knowable at the moment of decision into a teaching data pack. This is an independent teaching simulation based on that official public source. It is not real correspondence and not real client results, and it does not imply that Analysis Group used, reviewed, endorsed, sponsored, certified, or commissioned Minerva Advisor.

The case opens with a large global pharmaceutical company facing rising research and development costs, declining returns on marketing investment, and mounting pricing pressure on its drugs. The core question is whether the current product portfolio can sustain growth, and if not, whether the management team should immediately expand research and development investment or pursue acquisitions to close the gap, or first build a time bound, falsifiable comparison across paths before committing capital.

This run produced a clear, auditable work receipt built from five items: one source document reviewed in full, four decision maker roles identified, six known facts separated from two inferences, three open questions preserved rather than resolved, and two investment paths compared side by side. Three alternative explanations and one reversal condition were also preserved on the record.

Here is what was known and unknown at decision time. Known: cost and return pressures were rising, and the company was pursuing growth simultaneously through research and development, marketing, and acquisitions. Unknown: the risk adjusted contribution of the current portfolio, the success probability of each growth path, the capital required, the integration risk of any acquisition, and which assumptions the outcome was most sensitive to. Minerva did not treat any single point forecast as a certain outcome.

The strongest challenge came from advisor Evelyn, who asked whether building a full comparison would cause the team to miss the market window entirely. If a competitor locks in a key target first, or price erosion outpaces the portfolio's ability to adjust, waiting for a complete comparison could be worse than making an imperfect investment now. This objection was kept on the executive's screen as the defined reversal condition: if evidence shows the growth gap widening faster than the comparison timeline allows, the recommendation reverses toward immediate expansion.

The published answer was excluded from what Minerva saw. Analysis Group later disclosed that the company built a six week integrated model spanning research and development, marketing, and business development scenarios, then significantly adjusted its business development targets and reallocated investment toward smaller therapeutic areas. None of that later material was included in the input. Minerva did not treat the official model or the company's actual resource allocation as its own answer.

Three advisors cross-checked one judgment. Marcus defined the real bottleneck as the absence of a common comparison baseline across paths. Sofia modeled the downstream consequences for research and development, finance, business development, and the investment committee. Evelyn stress tested the timing risk of waiting. All three converged on the same direction: build a time bound, reversible portfolio comparison first, then let the human committee make the capital decision.

The executive was able to test whether adding new input would change the recommendation. The condition entered was that the common baseline must list success probability, capital requirements, downside scenarios, and the time window together, and that if the window is about to close, a limited, reversible advance commitment may be proposed alongside the comparison. The system recorded this as a response receipt. The original judgment stood, but the reversal condition became more specific and time bound.

Weighing the two options: immediately expanding research and development or pursuing acquisitions might capture a closing time window, but without quantifying the growth gap and success rates, it risks an irreversible misallocation of capital. Building a time bound portfolio comparison first lets every path share the same assumptions and downside thresholds, at the cost of delaying some opportunities. The executive selected the comparison path while keeping the time based reversal signal active.

The committed next action: finance, portfolio strategy, and business development teams are jointly tasked to quantify, within a fixed evaluation window, the current portfolio's contribution along with the shared assumptions and downside thresholds across research and development, marketing, and acquisition paths, then submit findings to the investment committee. Minerva Advisor does not make investment or medical decisions on a company's behalf.

This Analysis Group case passed all ten out of ten decision quality checks. The run used four model calls, delivered the first decision in 16.986 seconds, and completed the full result, including the three advisor cross-check, in 24.398 seconds. That is within the 30 second first decision threshold and the 45 second complete result threshold. Decision quality, executive experience, and performance all passed. This remains a single case test and does not represent production service levels or real customer outcomes.